In 2023, the sales of systemic hormonal preparations (excluding sex hormones and insulins) in Canada were observed at a certain baseline. Forecasted sales figures show a steady annual growth from 2024 to 2028, with values rising from 585.8 million USD in 2024 to 667.0 million USD in 2028. This indicates a consistent upward trend, reflective of a stable demand increase in this segment.
The compound annual growth rate (CAGR) for this period suggests a moderate but steady increase, pointing towards a healthy market. Year-on-year growth is consistent, averaging around 3-4%, underscoring a positive market outlook.
Future trends to watch include:
- Potential impact of technological advancements in pharmaceuticals.
- Regulatory changes impacting drug approvals and pricing.
- Shifts in healthcare policies and insurance coverage.
- Evolution of diseases influencing treatment paradigms.
